2019
Mixed‐methods approach to exploring patients’ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance
Tan W, Teo C, Chan D, Heinrich M, Feber A, Sarpong R, Allan J, Williams N, Brew‐Graves C, Ng C, Kelly J, Khetrapal P, ridhar A, Baker H, Ocampo F, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Dann A, Cook J, Cornwell M, Mills R, Knight H, Maher S, Rane A, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Dawson L, Roberts H, Main C, Jain S, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, inclair A, Storr E, Cogley L, Natale S, Lovegrove W, Smith S, Smith K, Hewitt D, Sriram R, Atkinson K, Royle L, Madine J, MacLean K, Walsh J, Guerdette M, Hill M, Payne D, Power A, Cannon J, Devereaux L, Thompson A, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Wardle H, Wilson D, Bayles A, Pelluri S, Pati J, Gherman A, Scott C, Madaan S, Taylor A, Edmunds E, Moore J, Rees A, Williams S, Caddy S, Dukes S, Goffe A, Buckhorn K, Nichols L, Acher P, Baillie K, Middleton K, Proctor C, Cresswell J, Chilvers A, Cain M, Vaux A, Watson D, Bradfield S, Gregory H, Mostafid H, Kehoe L, Drakeley S, Davies A, Williamson L, Krishnan R, Lunt N, Hill P, Burns H, Townley B, Wilkinson L, Wassall H, Hunt J, Holbrook B, Stancombe L, Morrison J, Vankoutrik L, Misra S, Fossey G, Richards A, Mcdonald K, Henderson A, Fennelly R, Tribbeck M, Ames K, Borwell J, Kotze M, Beesley K, Rennie K, Porter T, Gipson A, Piper L, Bailey L, Chrisopoulou A, Slevin K, McCartin F, Warburton H, Hathaway‐Lees S, Whetton K, Delves G, Day A, Bankole T, Broadhead S, Malde S, Oblak M, Ellis D, Bishara S, Barias‐Lara T, Donkov I, Thatcher H, Morris M, Culmsee C, Menzies H, Bartlett C, Cutting C, O'Brien N, Jannapureddy R, Kelkar A, Fitzgerald J, Longhurst S, Worth C, Peracha M, Mzazi S, Poile C, Griffiths L, Cook A, Barber N, Brar N, lty A, Zelhof B, Blades R. Mixed‐methods approach to exploring patients’ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. BJU International 2019, 124: 408-417. PMID: 30694612, PMCID: PMC6767410, DOI: 10.1111/bju.14690.Peer-Reviewed Original ResearchConceptsMinimally acceptable sensitivityAdverse eventsMixed-methods approachUrine biomarkersUrinary biomarkersProspective multicentre observational studyUrinary biomarker testsUrinary tract symptomsHome to hospitalAssociated with adverse eventsUrinary tract infectionHigh-risk patientsMulticentre observational studySensitivity of cystoscopyBladder cancer surveillanceDiagnosis of cancerSemi-structured interviewsPrevalence of haematuriaPatient experiencePatient perspectivePatients' viewsCancer surveillanceTract infectionsUrine biomarker studiesPatient demographics
2018
Novel urinary biomarkers for the detection of bladder cancer: A systematic review
Tan W, Tan W, Tan M, Khetrapal P, Dong L, deWinter P, Feber A, Kelly J. Novel urinary biomarkers for the detection of bladder cancer: A systematic review. Cancer Treatment Reviews 2018, 69: 39-52. PMID: 29902678, DOI: 10.1016/j.ctrv.2018.05.012.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueUrinary biomarkersBladder cancerReceiver operating characteristicRisk of biasPredictive valueNon-muscle invasive bladder cancer patientsBiomarkers investigated to dateInvasive bladder cancer patientsDetection of bladder cancerDiagnosis of bladder cancerSystematic reviewNovel urinary biomarkersBladder cancer patientsQUADAS-2 toolCase-control studyAssessed risk of biasSpecificity of biomarkersPositive test resultsSystematic searchUrinary cytologySurveillance cystoscopyComprehensive systematic reviewQUADAS-2
2017
DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells
Tan W, Feber A, Dong L, Sarpong R, Rezaee S, Rodney S, Khetrapal P, de Winter P, Ocampo F, Jalil R, Williams N, Brew-Graves C, Kelly J. DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells. BMC Cancer 2017, 17: 767. PMID: 29141603, PMCID: PMC5688623, DOI: 10.1186/s12885-017-3758-7.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorClinical ProtocolsFemaleHumansLiquid BiopsyMaleProspective StudiesUrinary Bladder NeoplasmsConceptsNon-muscle invasive bladder cancerNon-muscle invasive bladder cancer patientsBladder cancerSurveillance cystoscopyUrinary testsRisk of urinary tract infectionPresence of bladder cancerHigh grade bladder cancerDetection of bladder cancerProspective multicentre observational studyRecurrent bladder cancerUpper tract imagingInvasive bladder cancerUrinary sediment cellsUrinary tract infectionNegative predictive valueMulticentre observational studyGrade bladder cancerBladder cancer surveillanceCystoscopy findingsTract infectionsUrine sample collectionHistopathological resultsCystoscopyInvasive proceduresUroMark—a urinary biomarker assay for the detection of bladder cancer
Feber A, Dhami P, Dong L, de Winter P, Tan W, Martínez-Fernández M, Paul D, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng K, Zeegers M, Bryan R, James N, Paramio J, Freeman A, Beck S, Kelly J. UroMark—a urinary biomarker assay for the detection of bladder cancer. Clinical Epigenetics 2017, 9: 8. PMID: 28163793, PMCID: PMC5282868, DOI: 10.1186/s13148-016-0303-5.Peer-Reviewed Original ResearchConceptsDetection of bladder cancerEpigenetic alterationsSequencing assayNovel high-throughputBladder cancerBackgroundBladder cancerNext-generation sequencing assayUrinary biomarkersDNA methylationMuscle-invasive bladder cancerUrinary biomarker assaysSediment DNAAnalysis pipelineVoided urine samplesDetection of BCPrimary BCHigh-throughputCystoscopic examinationVoided urineDNAIndependent cohortAssayBiomarker panelDiagnosed BCCancer